{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T11:57:10Z","timestamp":1792324630237,"version":"4.4.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T00:00:00Z","timestamp":1653004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,2,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Recent studies have reported that reduced-dose trimethoprim-sulfamethoxazole (TMP-SMX) may be effective in the treatment of Pneumocystis jirovecii pneumonia (PJP), but data are lacking for patients with hematologic malignancies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This retrospective study included all adult hematologic patients with PJP between 2013 and 2017 at 6 Swedish university hospitals. Treatment with 7.5\u201315 mg TMP\/kg\/day (reduced dose) was compared with &amp;gt;15\u201320 mg TMP\/kg\/day (standard dose), after correction for renal function. The primary outcome was the change in respiratory function (\u0394partial pressure of oxygen [PaO2]\/fraction of inspired oxygen [FiO2]) between baseline and day 8. Secondary outcomes were clinical failure and\/or death at day 8 and death at day 30.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of a total of 113 included patients, 80 patients received reduced dose and 33 patients received standard dose. The overall 30-day mortality in the whole cohort was 14%. There were no clinically relevant differences in \u0394PaO2\/FiO2 at day 8 between the treatment groups, either before or after controlling for potential confounders in an adjusted regression model (\u221213.6 mm Hg [95% confidence interval {CI}, \u221256.7 to 29.5 mm Hg] and \u22129.4 mm Hg [95% CI, \u221250.5 to 31.7 mm Hg], respectively). Clinical failure and\/or death at day 8 and 30-day mortality did not differ significantly between the groups (18% vs 21% and 14% vs 15%, respectively). Among patients with mild to moderate pneumonia, defined as PaO2\/FiO2 &amp;gt;200 mm Hg, all 44 patients receiving the reduced dose were alive at day 30.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In this cohort of 113 patients with hematologic malignancies, reduced-dose TMP-SMX was effective and safe for treating mild to moderate PJP.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciac386","type":"journal-article","created":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T21:27:11Z","timestamp":1653082031000},"page":"e1252-e1260","source":"Crossref","is-referenced-by-count":16,"title":["Treatment With Reduced-Dose Trimethoprim-Sulfamethoxazole Is Effective in Mild to Moderate <i>Pneumocystis jirovecii<\/i> Pneumonia in Patients With Hematologic Malignancies"],"prefix":"10.1093","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5859-1056","authenticated-orcid":false,"given":"Helena","family":"Hammarstr\u00f6m","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg , Gothenburg , Sweden"},{"name":"Department of Infectious Diseases, Region V\u00e4stra G\u00f6taland, Sahlgrenska University Hospital , Gothenburg , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Krifors","sequence":"additional","affiliation":[{"name":"Department of Physiology and Pharmacology, Karolinska Institutet , Stockholm , Sweden"},{"name":"Centre for Clinical Research V\u00e4stmanland, Uppsala University , Uppsala , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Athlin","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Faculty of Medicine and Health, \u00d6rebro University , \u00d6rebro , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanda","family":"Friman","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg , Gothenburg , Sweden"},{"name":"Department of Infectious Diseases, Region V\u00e4stra G\u00f6taland, Sahlgrenska University Hospital , Gothenburg , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karan","family":"Golestani","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Sk\u00e5ne University Hospital , Malm\u00f6 , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"H\u00e4llgren","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases in \u00d6sterg\u00f6tland and Department of Biomedical and Clinical Sciences, Link\u00f6ping University , Link\u00f6ping , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisela","family":"Otto","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Sk\u00e5ne University Hospital , Lund , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Oweling","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases in \u00d6sterg\u00f6tland and Department of Biomedical and Clinical Sciences, Link\u00f6ping University , Link\u00f6ping , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karlis","family":"Pauksens","sequence":"additional","affiliation":[{"name":"Section of Infectious Diseases, Department of Medical Sciences, Uppsala University , Uppsala , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelie","family":"Kinch","sequence":"additional","affiliation":[{"name":"Section of Infectious Diseases, Department of Medical Sciences, Uppsala University , Uppsala , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola","family":"Blennow","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Karolinska University Hospital , Stockholm , Sweden"},{"name":"Unit of Infectious Diseases, Department of Medicine Huddinge, Karolinska Institute , Stockholm , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,5,20]]},"reference":[{"key":"2023020817015885200_ciac386-B1","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1186\/s12879-021-06144-1","article-title":"Epidemiological and clinical characteristics of immunocompromised patients infected with Pneumocystis jirovecii in a twelve-year retrospective study from Norway","volume":"21","author":"Gr\u00f8nseth","year":"2021","journal-title":"BMC Infect Dis"},{"key":"2023020817015885200_ciac386-B2","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/sj.bmt.1705149","article-title":"Occurrence of Pneumocystis jiroveci pneumonia after allogeneic stem cell transplantation: a 6-year retrospective study","volume":"36","author":"De Castro","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"2023020817015885200_ciac386-B3","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1046\/j.1365-2141.2002.03419.x","article-title":"Pneumocystis carinii pneumonia in patients with malignant haematological diseases: 10 years\u2019 experience of infection in GIMEMA centres","volume":"117","author":"Pagano","year":"2002","journal-title":"Br J Haematol"},{"issue":"Suppl 2","key":"2023020817015885200_ciac386-B4","doi-asserted-by":"crossref","first-page":"S416","DOI":"10.1093\/clinids\/17.Supplement_2.S416","article-title":"Pneumocystis carinii pneumonia in patients without AIDS","volume":"17","author":"Sepkowitz","year":"1993","journal-title":"Clin Infect Dis"},{"key":"2023020817015885200_ciac386-B5","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1093\/jac\/dkw158","article-title":"ECIL guidelines for treatment of Pneumocystis jirovecii pneumonia in non-HIV-infected haematology patients","volume":"71","author":"Maschmeyer","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2023020817015885200_ciac386-B6","doi-asserted-by":"crossref","first-page":"ofab545","DOI":"10.1093\/ofid\/ofab545","article-title":"On the treatment of Pneumocystis jirovecii pneumonia: current practice based on outdated evidence","volume":"8","author":"McDonald","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2023020817015885200_ciac386-B7","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.jcma.2016.01.007","article-title":"High daily doses of trimethoprim\/sulfamethoxazole are an independent risk factor for adverse reactions in patients with Pneumocystis pneumonia and AIDS","volume":"79","author":"Chang","year":"2016","journal-title":"J Chin Med Assoc"},{"key":"2023020817015885200_ciac386-B8","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jiac.2018.11.014","article-title":"Effectiveness and safety of lower dose sulfamethoxazole\/trimethoprim therapy for Pneumocystis jirovecii pneumonia in patients with systemic rheumatic diseases: a retrospective multicenter study","volume":"25","author":"Ohmura","year":"2019","journal-title":"J Infect Chemother"},{"key":"2023020817015885200_ciac386-B9","doi-asserted-by":"crossref","first-page":"ofaa112","DOI":"10.1093\/ofid\/ofaa112","article-title":"Low-dose TMP-SMX in the treatment of Pneumocystis jirovecii pneumonia: a systematic review and meta-analysis","volume":"7","author":"Butler-Laporte","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2023020817015885200_ciac386-B10","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium","volume":"71","author":"Donnelly","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"Suppl 2","key":"2023020817015885200_ciac386-B11","doi-asserted-by":"crossref","first-page":"S114","DOI":"10.1093\/cid\/ciaa1805","article-title":"Pneumocystis jirovecii disease: basis for the revised EORTC\/MSGERC invasive fungal disease definitions in individuals without human immunodeficiency virus","volume":"72","author":"Lagrou","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2023020817015885200_ciac386-B12","doi-asserted-by":"crossref","first-page":"e01173-17","DOI":"10.1128\/AAC.01173-17","article-title":"A four-center retrospective study of the efficacy and toxicity of low-dose trimethoprim-sulfamethoxazole for the treatment of Pneumocystis pneumonia in patients without HIV infection","volume":"61","author":"Kosaka","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2023020817015885200_ciac386-B13","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1186\/s13054-019-2663-7","article-title":"The SOFA score-development, utility and challenges of accurate assessment in clinical trials","volume":"23","author":"Lambden","year":"2019","journal-title":"Crit Care"},{"key":"2023020817015885200_ciac386-B14","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/BF01709751","article-title":"The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction\/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine","volume":"22","author":"Vincent","year":"1996","journal-title":"Intensive Care Med"},{"key":"2023020817015885200_ciac386-B15","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"2023020817015885200_ciac386-B16","volume-title":"Common Terminology Criteria for Adverse Events (CTCAE) version 5.0"},{"issue":"13 Spec No","key":"2023020817015885200_ciac386-B17","first-page":"47","article-title":"Treatment of Pneumocystis carinii pneumonitis with trimethoprim-sulfamethoxazole","volume":"112","author":"Hughes","year":"1975","journal-title":"Can Med Assoc J"},{"key":"2023020817015885200_ciac386-B18","doi-asserted-by":"crossref","first-page":"663","DOI":"10.7326\/0003-4819-100-5-663","article-title":"Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies","volume":"100","author":"Kovacs","year":"1984","journal-title":"Ann Intern Med"},{"key":"2023020817015885200_ciac386-B19","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jmii.2017.07.007","article-title":"Low-dose trimethoprim-sulfamethoxazole treatment for Pneumocystis pneumonia in non-human immunodeficiency virus-infected immunocompromised patients: a single-center retrospective observational cohort study","volume":"51","author":"Nakashima","year":"2018","journal-title":"J Microbiol Immunol Infect"},{"key":"2023020817015885200_ciac386-B20","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.chest.2018.04.026","article-title":"Early corticosteroids for Pneumocystis pneumonia in adults without HIV are not associated with better outcome","volume":"154","author":"Wieruszewski","year":"2018","journal-title":"Chest"},{"key":"2023020817015885200_ciac386-B21","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s10096-002-0758-5","article-title":"Analysis of underlying diseases and prognosis factors associated with Pneumocystis carinii pneumonia in immunocompromised HIV-negative patients","volume":"21","author":"Roblot","year":"2002","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2023020817015885200_ciac386-B22","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s10096-020-04118-w","article-title":"Characteristics and outcome according to underlying disease in non-AIDS patients with acute respiratory failure due to Pneumocystis pneumonia","volume":"40","author":"Burghi","year":"2021","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2023020817015885200_ciac386-B23","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1183\/09031936.00095811","article-title":"Quantitative PCR to diagnose Pneumocystis pneumonia in immunocompromised non-HIV patients","volume":"39","author":"M\u00fchlethaler","year":"2012","journal-title":"Eur Respir J"},{"key":"2023020817015885200_ciac386-B24","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13613-019-0604-x","article-title":"Outcome and prognostic factors of Pneumocystis jirovecii pneumonia in immunocompromised adults: a prospective observational study","volume":"9","author":"Gaborit","year":"2019","journal-title":"Ann Intensive Care"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciac386\/44329460\/ciac386.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/76\/3\/e1252\/49124358\/ciac386.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/76\/3\/e1252\/49124358\/ciac386.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T17:13:20Z","timestamp":1675876400000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/76\/3\/e1252\/6589787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,20]]},"references-count":24,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,5,20]]},"published-print":{"date-parts":[[2023,2,8]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciac386","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,2,1]]},"published":{"date-parts":[[2022,5,20]]}}}